Drugs / Copper Histidine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT00001262 | Jun 1990 → Jul 2012 | hair anomaly | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT00811785 | Feb 2009 → Aug 2020 | Menkes disease, occipital horn syndrome | Cyprium Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Copper Histidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001262 ↗ |
| Route | Subcutaneous | “the only treatment currently available is subcutaneous copper injections” PMID 25281031 ↗ Aug 2014 |